This research is Trending!
Evolocumab and risk of first myocardial infarction: the VESALIUS-CV trial
Gaetano Maria De FerrariRobert P. GiuglianoLawrence A. LeiterJosé Carlos NicolauAjay BhatiaMarcoli CyrilleJeong‐Gun ParkJulia KuderSabina A. MurphyLyrica LiuHuei WangAndrzej BudajJan CornelAndrej DžupinaAndrejs ĒrglisHenrik Kjærulf JensenRóbert Gábor KissJohanna KuusistoJosé López‐SendónAlberto LorenzattiG MontalescotStephen NichollsAlexander ParkhomenkoAxel SigurdssonMargus ViigimaaGabriel Paiva da Silva LimaMarc S. SabatineErin A. Bohula
Key result
Evolocumab investigation in the VESALIUS-CV trial abstract reports no clinical results on first MI risk.
Key Points
- To evaluate the efficacy of evolocumab in reducing the incidence of a first myocardial infarction in cardiovascular patients.
- Assessed cardiovascular outcomes associated with evolocumab therapy within the VESALIUS-CV clinical trial.
- Evaluates the occurrence and reduction of first myocardial infarction events following evolocumab administration.
Ask about this paper
Answers are grounded in this paper and cite their sources.
Key expert perspectives
Captured external expert commentary on this paper, strongest first. Original sources are linked where available.
“The results from the VESALIUS-CV trial represent the first demonstration of improved cardiovascular outcomes with a PCSK9 inhibitor, or any non-statin for that matter, in patients without a previous heart attack or stroke who are already being treated with a high-intensity lipid-lowering regimen.”
JSJoseph SaseenProfessor and associate dean, University of Colorado
“If you haven't heard of the VESALIUS-CV study and you manage patients who have lipid disorders, you need to read it—it's a game changer.”
Implication
Examines evolocumab and first myocardial infarction risk in cardiovascular patients, suggesting key implications for primary event prevention.
Abstract
No abstract yet. The journal hasn't published one we can show.
Discussion
No takes yet. Share an insight, caveat, or question.
Cite This Study
Ferrari et al. (2026) studied this question. Evolocumab was investigated for its effect on the risk of first myocardial infarction in the VESALIUS-CV trial, though no clinical results are provided in the abstract.